1. DEXAFP elicited a strong antigen-specific immune response.2. The tumor microenvironment was significantly improved following DEXAFP treatment, resulting an increase in CD8+ T lymphocytes and a decrease in regulatory T (Treg) cells. Here, CD8A is linked to neoplasm.